Samyang Biopharmaceuticals Corp. is a pharmaceutical company that was established in 2011 following the separation of the pharmaceutical business of Samyang.
Samyang Biopharmaceuticals Corp.'s pharmaceutical business is one of the three major growth drivers of the Samyang Group, along with the chemical and food businesses. Since its entry into the pharmaceutical business in 1995, Samyang Biopharmaceuticals Corp. has invested more than 20% of its annual sales in its pursuit of innovative R&D.
In doing so, we are engaged in new medical technology and pharmaceuticals, such as the drug delivery system (DDS), and are currently developing and conducting sales of anticancer drugs, Genexol® and Nanoxel® M, a smoking cessation patch, Nicostop®, and biodegradable surgical sutures, Trisorb® and Monosorb®.
In particular, Genexol® PM and Nanoxel® PM, which are anticancer drugs, continue to display excellent efficacy, such as the reduction of side effects by applying our own drug delivery technology (DDS). Also, our biodegradable surgical sutures are the third most successful medical device we produce and are exported to more than 150 customers in 45 countries around the world.
In April 2016, we completed construction of the Samyang Discovery Center in Pangyo Techno Valley, which has advanced R&D facilities. This center, viewed as a R&D mecca for Samyang Biopharmaceuticals Corp. will serve as the foundation for us to be defined as a global pharmaceutical company.
Moreover, Samyang Biopharmaceuticals Corp. has already been recognized as an innovative pharmaceutical company by the Ministry of Health and Welfare in 2012 based on our strong investment in R&D and technological prowess.
Samyang Biopharm will continuously develop pharmaceuticals and medical devices that will enhance human health and enrich the quality of life, and thereby secure the undoubted trust our customers, creating new values, facing the challenges of creating new values and innovation, nurturing talents, and furthermore, growing and progressing as a global pharmaceutical company.
We established Samyang Biopharm USA Inc. in Cambridge, MA in October 2018, and are expanding into immuno-oncology drugs and rare-diseases drugs market in the U.S